Skip to main content

Targeted Therapies


Guest-edited by:  Prof. Min Li, University of Oklahoma Health Sciences Center (OUHSC), USA
                             Dr. Yanis Boumber, Robert H Lurie Comprehensive Cancer Center, Feinberg                                     School of Medicine, Northwestern University, Chicago, USA 

New Content Item

BMC Medicine and BMC Cancer jointly present the "Targeted Therapies for Cancer" Collection 

Page 2 of 2

  1. The combination of bevacizumab and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) could prolong progression-free survival (PFS) in patients with EGFR-mutant advanced non-small-cell lung c...

    Authors: Yongchang Zhang, Liang Zeng, Xiangyu Zhang, Yizhi Li, Lingli Liu, Qinqin Xu, Haiyan Yang, Wenjuan Jiang, Analyn Lizaso, Luting Qiu, Ting Hou, Jun Liu, Ling Peng and Nong Yang
    Citation: BMC Medicine 2021 19:245
  2. With the identification of new targetable drivers and the recent emergence of novel targeted drugs, using comprehensive genomic profiling in lieu of the routine testing for classic drivers in the clinical care...

    Authors: Shen Zhao, Zhonghan Zhang, Jianhua Zhan, Xin Zhao, Xinru Chen, Liyun Xiao, Kui Wu, Yuxiang Ma, Mengzhen Li, Yunpeng Yang, Wenfeng Fang, Hongyun Zhao and Li Zhang
    Citation: BMC Medicine 2021 19:223
  3. Significant improvements in mortality among patients with non-small cell lung cancer (NSCLC) in the USA over the past two decades have been reported based on Surveillance, Epidemiology, and End Results (SEER) ...

    Authors: Sreeram Ramagopalan, Thomas P. Leahy, Joshua Ray, Samantha Wilkinson, Cormac Sammon and Vivek Subbiah
    Citation: BMC Medicine 2021 19:209
  4. Clinical effectiveness and safety data of pazopanib in patients with advanced or mRCC in real-world setting from Asia Pacific, North Africa, and Middle East countries are lacking.

    Authors: Mustafa Erman, Bivas Biswas, Pongwut Danchaivijitr, Lingwu Chen, Yoke Fui Wong, Tarek Hashem, Chun Sen Lim, Bulent Karabulut, Hsiao-Jen Chung, Chandrasekhar Chikatapu, Sara Ingles, Khemaies Slimane and Ravindran Kanesvaran
    Citation: BMC Cancer 2021 21:1021

    The Correction to this article has been published in BMC Cancer 2021 21:1191

  5. ROS1-rearranged lung cancers benefit from first-line crizotinib therapy; however, clinical and molecular factors that could affect crizotinib efficacy in ROS1-rearranged lung cancers are not yet well-elucidated. ...

    Authors: Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou, Jiexia Zhang, Zhengbo Song and Nong Yang
    Citation: BMC Medicine 2021 19:206
  6. Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all pati...

    Authors: Reid P. Bissonnette, Rosemary M. Cesario, Bob Goodenow, Farbod Shojaei and Mireille Gillings
    Citation: BMC Cancer 2021 21:969
  7. Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Human epidermal growth factor receptor 2 (HER2) amplification occurs in approximately 13–23% of all GC cases and patients wi...

    Authors: Gang Ning, Qihui Zhu, Wonyoung Kang, Hamin Lee, Leigh Maher, Yun-Suhk Suh, Michael Michaud, Mayerlin Silva, Jee Young Kwon, Chengsheng Zhang and Charles Lee
    Citation: BMC Cancer 2021 21:923
  8. Because lenvatinib is well known to induce proteinuria by blocking the vascular endothelial growth factor (VEGF) pathway, renal function is a concern with long-term administration of lenvatinib. The long-term ...

    Authors: Chie Masaki, Kiminori Sugino, Sakiko Kobayashi, Yoshie Hosoi, Reiko Ono, Haruhiko Yamazaki, Junko Akaishi, Kiyomi Y. Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama and Koichi Ito
    Citation: BMC Cancer 2021 21:894
  9. Pralatrexate (PDX) is a novel antifolate approved for the treatment of patients with relapsed/refractory peripheral T-cell lymphoma, but some patients exhibit intrinsic resistance or develop acquired resistanc...

    Authors: Kana Oiwa, Naoko Hosono, Rie Nishi, Luigi Scotto, Owen A. O’Connor and Takahiro Yamauchi
    Citation: BMC Cancer 2021 21:879
  10. This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients w...

    Authors: Stephen W. Booth, Toby A. Eyre, John Whittaker, Leticia Campo, Lai Mun Wang, Elizabeth Soilleux, Daniel Royston, Gabrielle Rees, Murali Kesavan, Catherine Hildyard, Farasat Kazmi, Nick La Thangue, David Kerr, Mark R. Middleton and Graham P. Collins
    Citation: BMC Cancer 2021 21:851
  11. Advanced stage marginal zone lymphoma (MZL) is an incurable indolent B-cell lymphoma, for which a wide variety of treatments ranging from single agent rituximab to more dose intense immunochemotherapy exists. ...

    Authors: Alexander Grunenberg, Lisa M. Kaiser, Stephanie Woelfle, Birgit Schmelzle, Andreas Viardot, Peter Möller, Thomas F. E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, Barbara Kiesewetter and Christian Buske
    Citation: BMC Cancer 2021 21:749
  12. Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second...

    Authors: Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung, Johannes Krisam, Marc A. Schneider, Albrecht Stenzinger, Regina Eickhoff, Daniel W. Mueller and Michael Thomas
    Citation: BMC Cancer 2021 21:743
  13. The more selective second-generation BTK inhibitors (BTKi) Acalabrutinib and Zanubrutinib and the first-generation BTKi Ibrutinib are highlighted by their clinical effectiveness in mantle cell lymphoma (MCL), ...

    Authors: Zhuojun Liu, Jia Liu, Tianming Zhang, Lin Li, Shuo Zhang, Hao Jia, Yuanshi Xia, Mingxia Shi, Jing Zhang, Shuhua Yue, Xiaofang Chen and Jian Yu
    Citation: BMC Cancer 2021 21:732
  14. Prolactin receptor (PRLR) is an attractive antibody therapeutic target with expression across a broad population of breast cancers. Antibody efficacy, however, may be limited to subtypes with either PRLR overe...

    Authors: Mark G. Anderson, Qian Zhang, Luis E. Rodriguez, Claudie M. Hecquet, Cherrie K. Donawho, Peter J. Ansell and Edward B. Reilly
    Citation: BMC Cancer 2021 21:681
  15. Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or intrinsic resistance often confounds therapy success. Com...

    Authors: Luis D. Borrero-García, Maria del Mar Maldonado, Julia Medina-Velázquez, Angel L. Troche-Torres, Luis Velazquez, Nilmary Grafals-Ruiz and Suranganie Dharmawardhane
    Citation: BMC Cancer 2021 21:652
  16. To compare the benefits and explore the cause of acquired resistance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and its combination with chemotherapy in advanced non-small-cell lu...

    Authors: Qianqian Wang, Wen Gao, Fangyan Gao, Shidai Jin, Tianyu Qu, Fan Lin, Chen Zhang, Jingya Zhang, Zhihong Zhang, Liang Chen and Renhua Guo
    Citation: BMC Cancer 2021 21:602
  17. The chemotherapy triplet FOLFOXIRI combined to the anti-VEGF antibody bevacizumab is an option in selected patients with metastatic colorectal cancer. In this setting, RAS-mutated metastatic colorectal cancer ...

    Authors: Antoine Adenis, Thibault Mazard, Julien Fraisse, Patrick Chalbos, Brice Pastor, Ludovic Evesque, Francois Ghiringhelli, Caroline Mollevi, Stéphanie Delaine and Marc Ychou
    Citation: BMC Cancer 2021 21:564
  18. Osimertinib is a third generation tyrosine kinase inhibitor (TKI) that targets the epidermal growth factor receptor (EGFR) in lung cancer. However, although this molecule is not subject to some of the resistan...

    Authors: Ulrich Jarry, Mégane Bostoën, Raphaël Pineau, Laura Chaillot, Valentine Mennessier, Pierre Montagne, Emilie Motte, Marjorie Gournay, Arnaud Le Goff, Thierry Guillaudeux and Rémy Pedeux
    Citation: BMC Cancer 2021 21:530

    The Correction to this article has been published in BMC Cancer 2021 21:574

Min Li

New Content ItemDr. Min Li is Professor of Medicine, Surgery, and Cell Biology at The University of Oklahoma Health Sciences Center (OUHSC), and holds the George Lynn Cross Research Professorship and the Virginia Kerley Cade Endowed Chair in Cancer Treatment. He is the Assistant Dean for International Research Collaboration at College of Medicine, and Associate Director for Global Oncology at the NCI designated Stephenson Cancer Center (SCC). He is also Director of GI Cancer Research, and Vice Chair for Research at the Department of Surgery, and Co-Leader of Cancer Biology Program of SCC at OUHSC. He is a leading expert on pancreatic cancer (PC), and his research mainly focus on studying PC and brain tumor pathogenesis and developing new therapies. Dr. Li’s group is the first to identify a key zinc transporter ZIP4, which is aberrantly expressed in PC, and promotes cancer growth, cachexia, and metastasis. He has published more than 180 papers and has 3 active NIH R01 grants, and multiple private foundation grants. 

Dr. Li is the council member of the International Association for Pancreatology (IAP), and councilor of the American Pancreatic Association (APA). He will be the President of APA in 2022. He received many awards such as the Outstanding Achievement Award of IAP, and the Provost Research Award. He is an Editorial Advisor for BMC Medicine

Yanis Boumber

New Content ItemYanis Boumber, MD, PhD, Associate Professor, Division of Hematology/ Oncology, Section of Thoracic Head and Neck Medical Oncology, at Northwestern University Cancer Center in Chicago. Dr. Boumber has previously worked as Assistant Professor in the Thoracic Section of the Department of Hematology/Oncology at the Fox Chase Cancer Center, Philadelphia, USA.

Dr Boumber graduated from the Rostov State Medical University, Russia and qualified as MD in 1999. He received his PhD in cancer biology and molecular biology at the University of Texas MD Anderson Cancer Center and the University of Texas Graduate School of Biomedical Sciences in Houston in 2005. He completed his medicine residency at Good Samaritan hospital, affiliated with Johns Hopkins University in Baltimore in 2010, and medical oncology and hematology fellowship at the University of Texas MD Anderson Cancer Center in 2013.

His research interests include the investigation of signaling pathways and biological processes controlled by MSI2 and developing novel therapeutic approaches to target MSI2 in lung cancer. He joined the editorial board of BMC Cancer in 2016 as Deputy Section Editor. He serves as Senior Board Member since August 2020.

About the Collection

Over the past two decades, significant progress has been made in understanding the molecular mechanisms of cancer, which has led to the development of molecular targeted agents including tyrosine kinase inhibitors, antiangiogenic agents, cell cycle and signalling targeting compounds, PARP inhibitors, DNA methylation inhibitors and antibody-drug conjugates. For many cancers including leukaemia, melanoma, lung, colorectal and breast cancer, targeted therapies have transformed the repertoire of currently available treatments, such as Vemurafenib for BRAF mutated metastatic melanoma and Herceptin for HER2 overexpressing breast cancer. Yet, the responses to targeted therapies are only marginal and short-lived, since many cancers develop resistance leading to disease progression, in addition to patients experiencing toxic side effects and financial burdens associated with treatment.

To overcome the problems associated with tumour resistance, research is focused on developing combination strategies involving targeted therapies and next-generation inhibitors with enhanced efficacy and selectivity. At the same time, molecular approaches are warranted to identify biomarkers and select the most suitable patients to optimise benefit and minimise toxicity.

In recognition of the growing field of research, BMC Medicine and BMC Cancer come together to invite submissions of original research including but not limited to:

  • Novel molecular targeted therapies, such as small molecules, antibodies and drug-antibody conjugates for new tumour targets
  • Resistance to conventional targeted therapies or the development of novel therapeutic targets that overcome targeted therapy resistance
  • Combination therapies involving targeted therapy
  • Discovery of novel serum/tumor biomarkers relevant to targeted therapies in clinical cohorts (e.g. from clinical trials)
  • Identification of genomic biomarkers relevant to targeted therapies through sequencing or bioinformatics (Please note: any bioinformatics studies must be experimentally validated or accompanied by real-world cohorts)
  • Survivorship and toxicology in patients treated with targeted or combination therapy regimens

For more information about each participating journal, including article-processing charges, click on its title below. After submitting to a participating journal, each article will undergo that journal’s full standard peer review process.

BMC Medicine encourages submissions of front matter articles and original research including randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), clinical “Real World” studies, cost-effectiveness analysis, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. For translational research we only consider studies that include patient cohorts or involves human samples. Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered. BMC Medicine does not consider case reports.

Guest Editors provided guidance on the scope of this collection and advised on commissioned content. However, they are not involved in editorial decision-making on papers submitted to this collection. All final editorial decisions are with the Editor-in-Chief, Dr. Lin Lee.​

BMC Cancer encourages submissions of original research and  study protocols reporting on randomised clinical trials (phase I, I/II, II and III as well as positive or negative trials), “Real World” studies, systematic reviews, medical imaging, genomic and serum biomarkers and translational research. BMC Cancer does not consider case reports. For pre-clinical and experimental research, we only consider studies that provide results validated in at least 3 relevant cell lines, preferably validated in at least one animal model.  Please note that manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation will not be considered.